Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
16
Active, not recruiting, industry sponsors, Pain and anesthesia, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed965
16 trials
Showing 1 to 16, recently updated first.
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Pivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06696443 · 455 participants · Start Dec 18, 2024 · Primary completion Jan 25, 2027
Drug: Suzetrigine · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Daphne, Alabama; Scottsdale, Arizona · 65 sites in all
- Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainPivotal-lookingActive, not recruiting
Saol Therapeutics IncIndustry
NCT07226258 · 150 participants (planned) · Start Nov 7, 2025 · Primary completion Nov 30, 2026
Drug: SL1002; Normal Saline · For: Osteoarthritis Knee Pain
Sites: Roseville, California; San Diego, California; Greenwood Village, Colorado · 22 sites in all
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigrainePivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT03836040 · 457 participants · Start Jul 19, 2019 · Primary completion Nov 19, 2025
Drug: Erenumab Dose 1; Erenumab Dose 2 and 1 more · For: Migraine
Sites: Ann Arbor, Michigan; Saint-Nicolas, Belgium; Medellín, Colombia · 11 sites in all
- A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05206773 · 122 participants · Start Mar 11, 2022 · Primary completion Dec 17, 2025
Drug: Venglustat (GZ402671); Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 50 sites in all
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07035093 · 586 participants (planned) · Start May 29, 2025 · Primary completion Sep 2027
Drug: Retatrutide; Placebo · For: Obesity; Overweight; Chronic Low Back Pain (CLBP)
Sites: Chandler, Arizona; Tucson, Arizona; Fountain Valley, California · 40 sites in all
- A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.Pivotal-lookingActive, not recruiting
Paradigm Biopharmaceuticals Ltd.Industry
NCT06917404 · 466 participants (planned) · Start May 29, 2025 · Primary completion Jul 2027
Drug: Pentosan Polysulfate Sodium twice weekly; Placebo · For: Osteoarthritis, Knee
Sites: Peoria, Arizona; Tucson, Arizona; Anaheim, California · 57 sites in all
- RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the KneePivotal-lookingActive, not recruiting
Overseas Pharmaceuticals, Ltd.Industry
NCT05318521 · 500 participants (planned) · Start Dec 10, 2021 · Primary completion Aug 12, 2022
Drug: Placebo; Ibuprofen modified release tablet 800 mg · For: Degenerative Arthritis
Sites: Cerritos, California; Garden Grove, California; Santa Ana, California · 11 sites in all
- A Study of TLC590 for Postsurgical Pain Following BunionectomyPivotal-lookingActive, not recruiting
TLC Biopharmaceuticals, Inc.Industry
NCT07222748 · 304 participants · Start Nov 17, 2025 · Primary completion Jun 12, 2026
Drug: TLC590; Liposomal Bupivacaine and 1 more · For: Postoperative Pain
Sites: Miami, Florida; Bellaire, Texas; Houston, Texas · 4 sites in all
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal SurgeryPivotal-lookingActive, not recruiting
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06890533 · 560 participants (planned) · Start May 14, 2025 · Primary completion Apr 17, 2026
Drug: Experimental: YZJ-4729; Placebo Comparator: Saline and 1 more · For: Pain
Sites: Cangzhou, China; Changde, China; Changsha, China · 49 sites in all
- Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainPivotal-lookingActive, not recruiting
Mesoblast, Ltd.Industry
NCT06325566 · 300 participants (planned) · Start Jul 3, 2024 · Primary completion Jul 2027
Drug: Rexlemestrocel-L + HA mixture; Saline · For: Degenerative Disc Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Chula Vista, California · 40 sites in all
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04333576 · 800 participants (planned) · Start Aug 10, 2020 · Primary completion Jul 2027
Drug: Elagolix; Placebo and 1 more · For: Endometriosis
Sites: Anniston, Alabama; Birmingham, Alabama; Dothan, Alabama · 179 sites in all
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigrainePivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04616326 · 312 participants · Start Nov 25, 2020 · Primary completion Dec 10, 2025
Drug: Galcanezumab; Placebo · For: Chronic Migraine
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 88 sites in all
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigrainePivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT03432286 · 533 participants · Start Mar 14, 2018 · Primary completion Nov 14, 2025
Drug: Galcanezumab; Placebo · For: Episodic Migraine
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 73 sites in all
- An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.Pivotal-lookingActive, not recruiting
Noema Pharma AGIndustry
NCT05217628 · 166 participants · Start Jan 11, 2022 · Primary completion Feb 2, 2027
Drug: Basimglurant · For: Trigeminal Neuralgia
Sites: La Jolla, California; Miami, Florida; Tampa, Florida · 34 sites in all
- Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA PainPivotal-lookingActive, not recruiting
Paradigm Biopharmaceuticals USA (INC)Industry
NCT04809376 · 602 participants · Start Oct 19, 2021 · Primary completion Oct 15, 2024
Drug: Pentosan Polysulfate Sodium twice weekly; Placebo (Sodium Chloride Injection, 0.9%) and 2 more · For: Osteoarthritis, Knee
Sites: Tempe, Arizona; Tucson, Arizona; Cerritos, California · 33 sites in all
- Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain AbdominoplastyPivotal-lookingActive, not recruiting
Avenue Therapeutics, Inc.Industry
NCT03774836 · 360 participants (planned) · Start Dec 14, 2018 · Primary completion May 30, 2019
Drug: Tramadol; Morphine · For: Pain Management
Sites: Pasadena, California; Houston, Texas; San Antonio, Texas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.